Skip to content
OpenCapital
Get started

Ginkgo Bioworks DNA Pharmaceutical and biotechnology — Concentration risk

Other product segments

Government and defense
35%+119%
Agriculture
13%-68.3%
Food and nutrition
7%+75.0%
Industrial and environment
7%0.0%
Consumer and technology
0%-100%

Similar metrics at other companies

PBH
PBHContract Pharmacal Corporation — Concentration risk, percentage
23%0.0pp
Simulations Plus logo
SLPClinical Operations — Concentration risk, percentage
3%-4.0pp
Weis Markets logo
WMKPharmacy — Concentration Risk %
13.2%+0.9pp
CryoPort, Inc. logo
CYRXLife Sciences Services — Concentration Risk %
2.6%—
Enovix Corporation logo
ENVXProduct — Concentration risk, percentage
83%+36.0pp
BrightSpring Health Services, Inc. logo
BTSGPharmacy Solutions — Concentration Risk %
87.8%-0.2pp

Other financials

Income statement

See full
Revenue$19.5M-49.1%
Gross profit$16.4M-52.0%
Operating income-$71.4M+11.9%
Net income-$82.6M+9.2%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$188.7M-46.9%
Total debt$410.7M-5.5%
Total equity$443.2M-31.6%
Total assets$1.0B-20.1%

Cash flow

See full
Operating cash flow-$46.7M+9.4%
CapEx$1.9M-74.6%
Free cash flow-$48.6M+17.8%

Valuation

See full
Market cap$625.16M+24.6%
Enterprise value$847.19M+45.9%
P/S4.4×+2.2×

Profitability

See full
Operating margin-210.7%+7.6pp
Net margin-215.4%+8.3pp
FCF margin-119%-21.2pp

Returns & leverage

See full
Return on equity-55.8%-1.8pp
Debt / equity0.9×+0.3×
Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:ConcentrationRiskPercentage1.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's pharmaceutical and biotechnology — concentration risk.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ginkgo Bioworks's pharmaceutical and biotechnology — concentration risk?
Ginkgo Bioworks (DNA) reported pharmaceutical and biotechnology — concentration risk of 38% in Q1 2026.
How has Ginkgo Bioworks's pharmaceutical and biotechnology — concentration risk changed year-over-year?
Ginkgo Bioworks's pharmaceutical and biotechnology — concentration risk increased by 22.6% year-over-year, from 31% to 38%.
What does pharmaceutical and biotechnology — concentration risk mean?
This metric represents the aggregate exposure or reliance on a specific set of clients or projects within the pharmaceutical and biotechnology sector. It highlights the potential impact on revenue stability if a major partner or program within this vertical were to terminate its engagement. Monitoring this risk is essential for assessing the diversification of the company's service portfolio.